Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group, Phase 3, Randomized, Open-label, 2-arm Study to Demonstrate the Superiority of Belumosudil Versus Best Available Therapy (BAT) in Participants at Least 12 Years of Age With Chronic Graft Versus Host Disease (cGVHD) Refractory to or Recurrent After 2 to 5 Prior Lines of Systemic Therapy

NCT07771439 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07771439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07771439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group, Phase 3, Randomized, Open-label, 2-arm Study to Demonstrate the Superiority of Belumosudil Versus Best Available Therapy (BAT) in Participants at Least 12 Years of Age With Chronic Graft Versus Host Disease (cGVHD) Refractory to or Recurrent After 2 to 5 Prior Lines of Systemic Therapy
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 7, 2026
Completion date
March 2, 2032
Enrollment
356 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft versus host disease